Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | POLQ | O75417 | 2/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956796 | 0.85 | NR1H2 (0.55) | MAOBPPARGPPARAPPARDMRGPRX4 | |
| SCHEMBL1008243 | 0.85 | MAOB (0.61) | MAOBPPARGPPARAPPARDMRGPRX4 | |
| SCHEMBL6087578 | 0.80 | MRGPRX4 (0.48) | MAOBMRGPRX4POLQSRD5A1MAPT | |
| SCHEMBL701131 | 0.79 | ALDH1A1 (0.61) | HTTMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL1009025 | 0.78 | PPARA (0.46) | MAOBPPARGPPARAMAPTL3MBTL1 | |
| SCHEMBL1009992 | 0.77 | PPARG (0.47) | PPARGPPARAPPARDHTTALDH1A1 | |
| SCHEMBL1008116 | 0.76 | LTB4R (0.61) | MAOBPPARGPPARANR4A2L3MBTL1 | |
| SCHEMBL6088493 | 0.76 | MRGPRX4 (0.50) | MAOBMRGPRX4NR4A2RXRANR1H2 | |
| SCHEMBL31285834 | 0.76 | PPARA (0.57) | MAOBPPARGPPARAMRGPRX4RXRA | |
| SCHEMBL2008583 | 0.76 | PPARA (0.57) | MAOBPPARGPPARAMRGPRX4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234464-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-09-16 | — | — | US | disclosed |
| EP-2026659-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007146768-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234464-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PC, GOT2, OAT | MAOB 822/4885PPARG 40/4885PPARA 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.